IN RE: Androgel Antitrust Litigation (No. II)

Track this case

Case Number:

1:09-md-02084

Court:

Georgia Northern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Thomas W. Thrash, Jr

Firms

Companies

Government Agencies

Federal Trade Commission

Sectors & Industries:

August 11, 2015
Drugmakers Fight FTC Bid For Privileged Antitrust Risk Docs

AbbVie Products LLC and other drugmakers being sued by the Federal Trade Commission and private plaintiffs over patent pay-for-delay settlements for testosterone drug AndroGel have told a Georgia federal court to reject a bid that would force them to turn over details of their settlement negotiations.
July 27, 2015
FTC Asks AbbVie, Others For Deal Docs In Pay-For-Delay Suit

The Federal Trade Commission and private plaintiffs suing AbbVie Products LLC and other drugmakers over patent pay-for-delay settlements for testosterone drug AndroGel moved Friday to force the companies to turn over details of their settlement negotiations.
October 24, 2013
AndroGel Judge Says It's Time To Revive Class Fight

A Georgia federal judge said Wednesday that he would overturn his dismissal of so-called pay-for-delay claims against Actavis Inc. and others in a putative class action over AndroGel in light of a recent U.S. Supreme Court ruling — if the Eleventh Circuit agrees to remand the case.
September 28, 2012
Sham Litigation Claims Nixed In Androgel Pay-For-Delay MDL

A Georgia federal judge on Friday dismissed antitrust allegations that Solvay Pharmaceuticals Inc. filed sham patent infringement litigation against generic rivals in order to delay the entry of competing versions of Androgel from the market through a reverse payment settlement.
May 18, 2011
Firms, Experts Allowed To Stay In AndroGel MDL

Solvay Pharmaceuticals Inc. and two other drugmakers on Tuesday lost bids to disqualify two expert witnesses and two law firms from multidistrict litigation in Georgia over whether the companies' AndroGel patent settlements violated antitrust law.
March 24, 2011
Solvay Wants Firms, Expert Removed In AndroGel Suit

Solvay Pharmaceuticals Inc. and two other drugmakers on Tuesday sought to disqualify an expert witness and two law firms from multidistrict litigation in Georgia over whether the companies' AndroGel patent settlements violated antitrust law.
September 17, 2010
Generics Subject To Solvay Sham Litigation Claims

A federal judge has kept alive claims alleging generics makers Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. engaged in sham litigation by agreeing not to release competing versions of Solvay Pharmaceuticals Inc.’s testosterone supplement AndroGel.
June 10, 2010
FTC Fights Nixing Of AndroGel Reverse Payment Suit

The Federal Trade Commission is challenging the dismissal of its claims accusing Solvay Pharmaceuticals Inc. of paying generic-drug makers not to compete with its testosterone supplement AndroGel, continuing the fight over so-called reverse payment settlements in the pharmaceutical industry.
March 08, 2010
AndroGel Buyer Seeks 2nd Shot At Pay-For-Delay Suit

An indirect purchaser of Solvay Pharmaceuticals Inc.'s testosterone supplement AndroGel has asked for leave to amend a recently dismissed putative class action accusing the drugmaker of keeping generics rivals out of the market by paying them through patent settlements.
February 23, 2010
AndroGel Reverse Payment Suits Thrown Out

A federal judge has thrown out suits by the Federal Trade Commission and private plaintiffs challenging patent settlements in which Solvay Pharmaceuticals Inc. paid generic-drug makers not to compete with its testosterone supplement AndroGel, joining other federal courts in upholding drug companies' right to make so-called reverse payment deals.